A randomized, double-blind, placebo-controlled trial of Abaloparatide men with osteoporosis at high risk for fracture

Trial Profile

A randomized, double-blind, placebo-controlled trial of Abaloparatide men with osteoporosis at high risk for fracture

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Abaloparatide (Primary)
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 21 Nov 2017 New trial record
    • 02 Nov 2017 According to Radius media release,the compnay expect to initiate this trial in the first quarter of 2018.
    • 02 Nov 2017 According to Radius media releas, the compnay has received an agreement with the FDA on the design of this trial which, if successful, will form the basis of an sNDA seeking to expand the use of TYMLOS to treat men with osteoporosis at high risk for fracture.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top